Analysts See $-0.31 EPS for Adverum Biotechnologies, Inc. (ADVM)

July 14, 2018 - By James Guidry

Analysts expect Adverum Biotechnologies, Inc. (NASDAQ:ADVM) to report $-0.31 EPS on August, 14.They anticipate $0.04 EPS change or 14.81 % from last quarter’s $-0.27 EPS. After having $-0.30 EPS previously, Adverum Biotechnologies, Inc.’s analysts see 3.33 % EPS growth. The stock decreased 4.63% or $0.25 during the last trading session, reaching $5.15. About 371,972 shares traded. Adverum Biotechnologies, Inc. (NASDAQ:ADVM) has risen 132.08% since July 14, 2017 and is uptrending. It has outperformed by 119.51% the S&P500.

Adverum Biotechnologies, Inc., a gene therapy company, discovers and develops novel medicines for patients suffering from rare diseases or diseases of eye. The company has market cap of $320.70 million. The firm has a pipeline that includes product candidates to treat wet age-related macular degeneration , alpha 1 antitrypsin deficiency (A1AT), and hereditary angioedema. It currently has negative earnings. The Company’s lead gene therapy programs include ADVM-022 and ADVM-032, which are in the preclinical development of new anti-VEGF gene therapy candidates for wAMD diseases; and ADVM-043, which is in patient enrollment in a phase 1/2 trial for the treatment of A1AT.

Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: